Marevan (Warfarin Sodium)

Warfarin blocks the enzyme vitamin K epoxide reductase, which is essential for recycling vitamin K in the liver. Without active vitamin K, the body cannot produce the clotting factors II, VII, IX, and X that are required for normal blood coagulation. This reduction in clotting factor levels diminishes thrombin generation and slows the formation of fibrin clots, providing an anticoagulant effect.

The dose of Marevan is individualized by a qualified prescriber based on the patient’s clinical condition, age, weight, liver function, and especially the result of regular INR (International Normalized Ratio) testing. The prescriber adjusts the amount to keep the INR within a therapeutic range that balances clot‑prevention benefits with bleeding risk. No fixed dosing schedule can be provided without professional assessment.

Marevan is classified as Pregnancy Category X, meaning it is contraindicated during pregnancy because it can cross the placenta and cause fetal malformations, bleeding, or death. It is also not recommended for breastfeeding mothers, as warfarin can be excreted in breast milk and may affect the infant’s coagulation. Alternative anticoagulants should be considered in these situations.

To request Marevan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide and will ask for trade or institutional credentials. After verification, the sales team provides pricing, availability, shipping details—including any special handling—and assists with the necessary import documentation.

Marevan (warfarin) is a long‑standing oral vitamin K antagonist that requires regular INR monitoring and dose adjustments. Direct oral anticoagulants (DOACs) such as apixaban or rivaroxaban have more predictable pharmacokinetics and do not need routine monitoring, but they may be more expensive and have different renal clearance considerations. Choice of therapy depends on patient-specific factors, drug interactions, and clinical guidelines.

Marevan tablets should be stored at room temperature, below 25 °C, in their original container to protect them from moisture and light. Keep the medication out of reach of children and do not store in bathrooms or other humid areas. Do not use tablets that are discolored, broken, or past the expiry date.

Marevan is taken orally, usually once daily, with or without food as directed by the prescriber. The tablet should be swallowed whole with a full glass of water. Patients should follow the dosing schedule provided by their healthcare professional and attend regular clinic visits for INR monitoring to ensure the dose remains appropriate.

The most serious risks include severe bleeding events such as intracranial hemorrhage, gastrointestinal bleeding, and skin necrosis. Patients should be alert for sudden severe headache, weakness, vision changes, blood in urine or stool, unexplained bruising, or painful skin lesions. Any of these signs require immediate medical attention, as they may indicate life‑threatening complications.

Marevan is contraindicated in individuals with active major bleeding, recent intracranial or spinal surgery, uncontrolled hypertension, severe liver disease, or known hypersensitivity to warfarin. It should also be avoided in pregnant women and those planning pregnancy. Patients with a history of warfarin‑induced skin necrosis or those taking certain interacting medications without close monitoring should not use Marevan without specialist guidance.